Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9

  • Hui Li
  • Po Hu
  • Zhanyu Wang
  • Hongzheng Wang
  • Xiaoxuan Yu
  • Xiangyuan Wang
  • Yingjie Qing
  • Mengyuan Zhu
  • Jingyan Xu
  • Zhiyu Li
  • Qinglong GuoEmail author
  • Hui HuiEmail author
Genotoxicity and Carcinogenicity


Mitotic catastrophe of cancer cells induced by drugs is characterized by low dosage and low toxicity, representing a significant advantage in the cancer treatment. Effective therapeutic options are limited for T-cell malignancies patients who are still treated by high-dose multiagent chemotherapy, potentially followed by hematopoietic stem cell transplantation, highlighting the urgency for identification of more effective anti-T-cell malignancies drugs. The use of antineoplastic drugs which induced tumor cell mitotic catastrophe would be a new strategy for cancer therapy. Nevertheless, there is still no effective mitotic catastrophe agent in T-cell malignancies. Our study showed that nonlethal dosage (ND) of GL-V9 (5-hydroxy-8-methoxy-2-phenyl-7-(4-(pyrrolidin-1-yl) butoxy) 4 H-chromen-4-one) (2 µM), a potential anticancer drug, not only attenuated cell growth and survival, but also arrested the cell cycle in G2/M phase and induced multipolar spindles, nuclear alterations (micronucleation and multinucleation), which are the most prominent morphological characteristics of mitotic catastrophe, in T-cell malignancies cell lines including Jurkat, HuT-102, and HuT-78. Moreover, ND GL-V9 could trigger DNA damage, and significantly influence several mitosis-associated proteins. Besides, results showed that ND GL-V9 increased the activity of senescence-associated β-galactosidase (SA-β-Gal) following the induction of mitotic catastrophe in Jurkat and HuT-102 cells with intact p53, while causing apoptosis in p53-deficient HuT-78 cells. We concluded that the anti-T-cell malignancies effects of ND GL-V9 and clarified the precise regulation in the process of mitosis under the action of GL-V9 in T-cell malignancies. Our data provided new evidence for the study of T-cell malignancies treatment associated with mitotic catastrophe and cellular senescence induction.


Mitotic catastrophe Cellular senescence p53 ND GL-V9 T-cell malignancies 



T-cell acute lymphoblastic leukemia


T cell non-Hodgkin lymphomas


Nonlethal dosage of GL-V9


Checkpoint kinase 1


Checkpoint kinase 2


Cyclin B1-dependent kinase


Mitotic arrest deficient 2


Polo-like kinases


Senescence-associated β-galactosidase


Poly (ADP-ribose) polymerase


Carboxyfluorescein diacetate succinimidyl ester


Minimal residual disease



This work was supported by the Drug Innovation Major Project (Nos. 2017ZX09301014, 2018ZX09711001-003-007, 2017ZX09101003-005-023), the National Science and Technology Major Project (No. 2018ZX09711001-005-023), the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (No. SKLNMZZCX201823), the Nation Natural Science Foundation of China (Nos. 81903647, 81503096, 81673461, 81873046, 81830105), Project funded by China Postdoctoral Science Foundation (No. 2018M642373), Natural Science Foundation of Jiangsu province (Nos. BK20190560 and BE2018711), Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT-IRT1193), Nanjing Medical Science and Technology Development Project (YKK17074), the Open Project of State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine (Nos. TCMQ and E201704), and “Double First-Class” University project (CPU 2018GF11, CPU2018GF05).

Author contributions

HL designed and performed research and analyzed data and wrote the manuscript; PH and ZW performed research. HW and XY analyzed data; YQ collected data; XW and MZ performed statistical analysis; JX edited the manuscript; ZL analyzed the compound; QG and HH conceptualized the project, directed experiment design and data analysis.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.


  1. Aasland D, Gotzinger L, Hauck L et al (2019) Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-kappaB. Cancer Res 79(1):99–113. CrossRefPubMedGoogle Scholar
  2. Aifantis I, Raetz E, Buonamici S (2008) Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8(5):380–390. CrossRefPubMedGoogle Scholar
  3. Andreassen PR, Lacroix FB, Lohez OD, Margolis RL (2001) Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res 61(20):7660–7668PubMedGoogle Scholar
  4. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5(3):231–237. CrossRefPubMedGoogle Scholar
  5. Bunz F, Dutriaux A, Lengauer C et al (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282(5393):1497–1501CrossRefGoogle Scholar
  6. Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol 75:685–705. CrossRefPubMedGoogle Scholar
  7. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23(16):2825–2837. CrossRefPubMedGoogle Scholar
  8. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401(6753):616–620. CrossRefPubMedGoogle Scholar
  9. Chen Z, Xiao Z, Chen J et al (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2(6):543–548PubMedGoogle Scholar
  10. Chen CJ, Hsu MH, Kuo SC, Lai YY, Chung JG, Huang LJ (2007) (2E)-N, N-dibutyl-3-(4-hydroxy-3-methoxyphenyl)acrylamide induces apoptosis and cell cycle arrest in HL-60 cells. Anticancer Res 27(1A):343–349PubMedGoogle Scholar
  11. Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9(8):616–627. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Cogswell JP, Brown CE, Bisi JE, Neill SD (2000) Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 11(12):615–623PubMedGoogle Scholar
  13. Dietlein F, Thelen L, Jokic M et al (2014) A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov 4(5):592–605. CrossRefPubMedGoogle Scholar
  14. Ditchfield C, Johnson VL, Tighe A et al (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161(2):267–280. CrossRefPubMedPubMedCentralGoogle Scholar
  15. Dixon H, Norbury CJ (2002) Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 1(6):362–368. CrossRefPubMedGoogle Scholar
  16. Eckerdt F, Yuan J, Strebhardt K (2005) Polo-like kinases and oncogenesis. Oncogene 24(2):267–276. CrossRefPubMedGoogle Scholar
  17. Eom YW, Kim MA, Park SS et al (2005) Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24(30):4765–4777. CrossRefPubMedGoogle Scholar
  18. Gire V, Dulic V (2015) Senescence from G2 arrest, revisited. Cell Cycle 14(3):297–304. CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hendzel MJ, Wei Y, Mancini MA et al (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106(6):348–360CrossRefGoogle Scholar
  20. Ianzini F, Mackey MA (1997) Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells. Int J Radiat Biol 72(4):409–421CrossRefGoogle Scholar
  21. Ingenhag D, Reister S, Auer F et al (2019) The homeobox transcription factor HB9 induces senescence and blocks differentiation in hematopoietic stem and progenitor cells. Haematologica 104(1):35–46. CrossRefPubMedPubMedCentralGoogle Scholar
  22. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461(7267):1071–1078. CrossRefPubMedPubMedCentralGoogle Scholar
  23. Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7(2):107–117. CrossRefPubMedGoogle Scholar
  24. Johmura Y, Shimada M, Misaki T et al (2014) Necessary and sufficient role for a mitosis skip in senescence induction. Mol Cell 55(1):73–84. CrossRefPubMedGoogle Scholar
  25. Kelly KR, Ecsedy J, Mahalingam D et al (2011) Targeting aurora kinases in cancer treatment. Curr Drug Targets 12(14):2067–2078CrossRefGoogle Scholar
  26. Khongkow P, Gomes AR, Gong C et al (2016) Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene 35(8):990–1002. CrossRefPubMedGoogle Scholar
  27. Krenning L, Feringa FM, Shaltiel IA, van den Berg J, Medema RH (2014) Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol Cell 55(1):59–72. CrossRefPubMedGoogle Scholar
  28. Kroemer G, Galluzzi L, Vandenabeele P et al (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 16(1):3–11. CrossRefPubMedGoogle Scholar
  29. Lens SM, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10(12):825–841. CrossRefPubMedGoogle Scholar
  30. Li L, Chen P, Ling Y et al (2011) Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Eur J Pharm Sci 43(5):393–399. CrossRefPubMedGoogle Scholar
  31. Li H, Xu J, Zhou Y et al (2017) PLSCR1/IP3R1/Ca(2+) axis contributes to differentiation of primary AML cells induced by wogonoside. Cell Death Dis 8(5):e2768. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Li H, Lu N, Yu X et al (2018) Oroxylin A, a natural compound, mitigates the negative effects of TNFalpha-treated acute myelogenous leukemia cells. Carcinogenesis 39(10):1292–1303. CrossRefPubMedGoogle Scholar
  33. Lopez-Contreras AJ, Fernandez-Capetillo O (2010) The ATR barrier to replication-born DNA damage. DNA Repair (Amst) 9(12):1249–1255. CrossRefGoogle Scholar
  34. Mansilla S, Bataller M, Portugal J (2006) Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med Chem 6(6):589–602CrossRefGoogle Scholar
  35. Mc Gee MM (2015) Targeting the mitotic catastrophe signaling pathway in cancer. Mediat Inflamm 2015:146282. CrossRefGoogle Scholar
  36. Muller A, Gillissen B, Richter A et al (2018) Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53. Cell Death Dis 9(3):384. CrossRefPubMedPubMedCentralGoogle Scholar
  37. Nitta M, Kobayashi O, Honda S et al (2004) Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 23(39):6548–6558. CrossRefPubMedGoogle Scholar
  38. Portugal J, Mansilla S, Bataller M (2010) Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des 16(1):69–78CrossRefGoogle Scholar
  39. Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updates 4(5):303–313. CrossRefGoogle Scholar
  40. Ross JA, Spadaro M, Rosado DC, Cavallo F, Kirken RA, Pericle F (2014) Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. Leukemia 28(4):941–944. CrossRefPubMedGoogle Scholar
  41. Sato N, Mizumoto K, Nakamura M, Tanaka M (2000) Radiation-induced centrosome overduplication and multiple mitotic spindles in human tumor cells. Exp Cell Res 255(2):321–326. CrossRefPubMedGoogle Scholar
  42. Schmit TL, Ahmad N (2007) Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 6(7):1920–1931. CrossRefPubMedGoogle Scholar
  43. Schrappe M, Hunger SP, Pui CH et al (2012) Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366(15):1371–1381. CrossRefPubMedPubMedCentralGoogle Scholar
  44. Smith J, Tho LM, Xu N, Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73–112. CrossRefPubMedGoogle Scholar
  45. Sorensen CS, Syljuasen RG (2012) Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 40(2):477–486. CrossRefPubMedGoogle Scholar
  46. Sudakin V, Yen TJ (2007) Targeting mitosis for anti-cancer therapy. BioDrugs 21(4):225–233. CrossRefPubMedGoogle Scholar
  47. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62(6):1876–1883Google Scholar
  48. Vakifahmetoglu H, Olsson M, Zhivotovsky B (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15(7):1153–1162. CrossRefPubMedGoogle Scholar
  49. Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12(6):385–392. CrossRefPubMedGoogle Scholar
  50. Weaver BA, Cleveland DW (2005) Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8(1):7–12. CrossRefPubMedGoogle Scholar
  51. Yang L, He Z, Yao J et al (2018) Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells. Redox Biol 17:180–191. CrossRefPubMedPubMedCentralGoogle Scholar
  52. Ye C, Zhang X, Wan J et al (2013) Radiation-induced cellular senescence results from a slippage of long-term G2 arrested cells into G1 phase. Cell Cycle 12(9):1424–1432. CrossRefPubMedPubMedCentralGoogle Scholar
  53. Yun M, Han YH, Yoon SH et al (2009) p31comet induces cellular senescence through p21 accumulation and Mad2 disruption. Mol Cancer Res 7(3):371–382. CrossRefPubMedGoogle Scholar
  54. Zhang X, Kang Y, Huo T et al (2017) GL-V9 induced upregulation and mitochondrial localization of NAG-1 associates with ROS generation and cell death in hepatocellular carcinoma cells. Free Radic Biol Med 112:49–59. CrossRefPubMedGoogle Scholar
  55. Zhao K, Li G, Yao Y et al (2017a) Activation of phospholipase C-gamma1 and translocation of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase contribute to GL-V9-induced apoptosis in human gastric cancer cells. Exp Cell Res 356(1):8–19. CrossRefPubMedGoogle Scholar
  56. Zhao Y, Guo Q, Zhao K et al (2017b) Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. Oncoimmunology 7(1):e1375640. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Jiangsu Key Laboratory of Drug Design and OptimizationChina Pharmaceutical UniversityNanjingPeople’s Republic of China
  2. 2.Department of HematologyThe Affiliated DrumTower Hospital of Nanjing University Medical SchoolNanjingPeople’s Republic of China

Personalised recommendations